From Promise to Proof

Our commitment to achieve the best possible results for every dialysis patient has fuelled our passion for haemodiafiltration (HDF). This passion rests on the firm belief that HDF is the best therapy for every patient.

Our conviction in HDF is now widely shared across the scientific community and backed by evidence. In recent years several publications have already confirmed the benefits of HDF.^1-7 The Catalonian high-volume HDF study¹ provides accumulating evidence for the benefits of this therapy. Convincing scientific evidence for significantly improved patient outcomes combined with the simple and safe use of the 5008 CorDiax are compelling reasons to switch to HighVolumeHDF – now.

That’s why for more than 30 years Fresenius Medical Care has been developing products for Cardioprotective Haemodialysis, leading to the CorDiax product line — which perfectly supports the application of HighVolumeHDF. 

_{¹ Maduell F. et al., J Am Soc Nephrol (2013); 24: 487-497.
² Ok E. et al., Nephrol Dial Transplant (2013); 28(1): 192-202.
³ Grooteman M.P. et al., J Am Soc Nephrol (2012); 23(6): 1087-96.
⁴ Canaud B. et al., Kidney Int (2006); 69(11): 2087-93.
5 Mostovaya I.M. et al., Semin Dial (2014); 27(2): 119-127.
6 Peters S.A.E. et al., Nephrol Dial Transplant (2016); 31: 978-984.
7 Basile C. et al., J Nephrol (2017); 30(2): 181-186.}